How has 4D Molecular Therapeutics's operating lease liabilities changed year-over-year?

4D Molecular Therapeutics's operating lease liabilities decreased by 16.4% year-over-year, from -$754K to -$878K.

What is the long-term trend for 4D Molecular Therapeutics's operating lease liabilities?

Over 3 years (2022 to 2025), 4D Molecular Therapeutics's operating lease liabilities has grown at a 114.4% compound annual growth rate (CAGR), from -$324K to -$3.19M.

4D Molecular Therapeutics FDMT Operating lease liabilities

Operating lease liabilities at other companies

PVL

Palvella TherapeuticsPVLA

——

Kodiak Sciences IncKOD

——

Rigel PharmaceuticalsRIGL

——

Prime MedicinePRME

——

Zevra Therapeutics, Inc.ZVRA

——

Other financials

Income statement

See full

Revenue$3.0M+21,664%

Operating income-$73.6M-37.3%

Net income-$68.8M-43.3%

EPS (diluted)-$1.01-17.4%

Balance sheet

See full

Cash & equivalents$72.5M-45.7%

Total debt$20.5M-13.9%

Total equity$451.8M-3.8%

Total assets$512.9M-0.5%

Cash flow

See full

Operating cash flow-$68.1M-42.6%

CapEx--100%

Free cash flow-$68.1M-40.8%

Valuation

See full

Market cap$602.22M+215%

Enterprise value$550.27M+574%

P/S6.8×-8,306×

Profitability

See full

Operating margin-220.1%-110pp

Net margin-174,314.2%-62,763pp

FCF margin-154,209.2%-53,057pp

Returns & leverage

See full

Return on equity-45.4%+29.8pp

Debt / equity0×0.0×

Current ratio9.3×-3.0×

Where this comes from

Reported directly by 4D Molecular Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about 4D Molecular Therapeutics's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is 4D Molecular Therapeutics's operating lease liabilities?: 4D Molecular Therapeutics (FDMT) reported operating lease liabilities of -$878K in Q1 2026.
How has 4D Molecular Therapeutics's operating lease liabilities changed year-over-year?: 4D Molecular Therapeutics's operating lease liabilities decreased by 16.4% year-over-year, from -$754K to -$878K.
What is the long-term trend for 4D Molecular Therapeutics's operating lease liabilities?: Over 3 years (2022 to 2025), 4D Molecular Therapeutics's operating lease liabilities has grown at a 114.4% compound annual growth rate (CAGR), from -$324K to -$3.19M.